Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients (NAPLESIII)
This study has been completed.
Information provided by (Responsible Party):
Carlo Briguori, Clinica Mediterranea
First received: November 1, 2011
Last updated: April 6, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, Ricciardelli B. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015 Mar;8(3):414-23. doi: 10.1016/j.jcin.2014.10.015.
Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, Ricciarelli B. Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting throught the femoral approach. rationale and design. Cardiovasc Drugs Ther. 2014 Jun;28(3):273-9. doi: 10.1007/s10557-014-6518-9.